Holen Sie sich die Stockscreener-App
1.24
2.48%
0.03
Handel nachbörslich:
1.24
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang
Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com
Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union
Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan
Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board - Quantisnow
TradingKey - TradingKey
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView
CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan
Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com
The industry tailwinds powering Pliant Therapeutics (PLRX) growth (Smart Money Flows) 2026-05-08Social Buy Zones - Newser
Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat
Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network
Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com South Africa
Pliant Therapeutics begins trial of cancer drug combination - Investing.com
Pliant Therapeutics Announces First Patient Dosed in - GlobeNewswire
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN
Pliant Therapeutics Inc (FRA:9PT) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell - MarketBeat
Pliant Therapeutics (NASDAQ: PLRX) outlines 2026 virtual meeting, board changes and pay vote - Stock Titan
[ARS] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan
Pliant Therapeutics, Inc. (PLRX) Presents at AACR Annual Meeting 2026Slideshow (NASDAQ:PLRX) 2026-04-21 - Seeking Alpha
Primary Sclerosing Cholangitis (PSC) Market is expected to Hit - openPR.com
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-101095 Trials - GuruFocus
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-1010 - GuruFocus
Pliant Therapeutics (PLRX) Stock: Movement Analysis (Breakout Watch) 2026-04-18Elite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Pliant presents updated cancer trial data at AACR meeting By Investing.com - Investing.com South Africa
Pliant Therapeutics presents updated Phase 1 data for PLN-101095 in ICI-refractory tumors - Traders Union
Pliant presents updated cancer trial data at AACR meeting - Investing.com
Pliant Therapeutics : Final AACR 2026 PLN10195 Yap - marketscreener.com
Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed - TradingView
Pliant Therapeutics Announces Presentation of Updated Data - GlobeNewswire
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):